We advised Zylox-Tonbridge Medical Technology on its IPO and HKEX listing

Davis Polk advised Zylox-Tonbridge Medical Technology Co., Ltd. in connection with its initial public offering and listing on the Hong Kong Stock Exchange in reliance on Rule 144A and Regulation S of the Securities Act of 1933. The gross proceeds from the offering amounted to approximately HK$2.56 billion (US$329 million) prior to any exercise of the over-allotment option.

Zylox-Tonbridge Medical Technology is a leading player in the neuro- and peripheral-vascular interventional medical device market in China, its current therapeutic areas include acute ischemic stroke (AIS), intracranial aneurysm, carotid artery stenosis, peripheral arterial and venous diseases and dialysis related diseases. Since its inception in 2012, Zylox-Tonbridge Medical Technology has systemically and methodically developed a portfolio of 45 products and product candidates to cover neuro- and peripheral-vascular device market and vascular closure device market that are highly under-penetrated and fast growing.

 The Davis Polk corporate team included partners Yang Chu, Li He and Xuelin (Steve) Wang, counsel Lillian Lian, registered foreign lawyers Jennifer Liu and Allie Ma and associate Sarah Shi. Counsel Alon Gurfinkel and associates Omer Harel and Summer Xia provided tax advice. Members of the Davis Polk team are based in the Hong Kong and London offices.